Full-Time

Lead GMP Manufacturing Support

Cleaning & Sanitization

Posted on 8/1/2025

Forge Biologics

Forge Biologics

201-500 employees

End-to-end manufacturing of AAV gene therapies

No salary listed

Columbus, OH, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Associate’s or Bachelor’s degree in a relevant scientific field (e.g., Biology, Chemistry, Engineering) or equivalent experience.
  • Minimum 5 years of experience in a GMP manufacturing environment, preferably in biologics, gene therapy, or sterile manufacturing.
  • Demonstrated leadership skills with experience overseeing or mentoring team members.
  • Strong understanding of cleanroom classifications, contamination control principles, and GMP regulations.
  • Experience working within a Quality Management System (QMS).
  • Proven experience overseeing manufacturing support functions (e.g., cleaning and sanitization, tube set building and setup).
  • Excellent communication, organization, and problem-solving skills.
  • Exceptional computer skills, prior experience with a manufacturing software (e.g., MRP or ERP System), and ability to use data analytics to drive process improvements and results.
  • Flexibility to work in shifts, including weekends and holidays, as required by manufacturing production schedules.
  • Ability to work in classified cleanroom environments (ISO 5–8 / Grade A–D) for extended periods while fully gowned in aseptic/sterile PPE attire.
  • Able to lift up to 40 pounds and remain standing or walking for extended periods throughout the shift.
Responsibilities
  • Lead the cleanroom cleaning team to perform routine and non-routine cleaning operations per SOPs and GMP requirements.
  • Oversee cleaning of aseptic fill areas, upstream/downstream suites, airlocks, corridors, and equipment in accordance with validated procedures.
  • Perform verification of cleaning and sanitization activities and ensure accurate documentation; perform the manufacturing review of logbooks and associated documents; and resolve out-of-trend situations promptly.
  • Act as SME for cleanroom behaviors, gowning, and contamination control best practices.
  • Support deviation investigations, root cause analysis, and CAPA development related to cleaning issues or contamination events.
  • Plan and assign daily tasks for effective resource utilization, collaborating with planning, and maintaining schedules.
  • Train and coach new and existing staff on cleaning techniques, gowning, aseptic behavior, and cleanroom discipline.
  • Collaborate with Manufacturing, Quality Assurance, Quality Control, Environmental Monitoring, and Facilities & Engineering to resolve issues and drive continuous improvement.
  • Support cleaning validation and requalification activities for classified spaces and equipment.
  • Manage cleanroom inventory to ensure availability of common-use items and uninterrupted operations.
  • Oversee consumable expiration tracking and storage, implementing rotation protocols and guiding technicians to meet operational and regulatory standards.
  • Other responsibilities may include supporting tubing sets preparation, process improvement initiatives and collaborating with cross-functional teams to ensure the efficient production of gene therapy products.
  • May assist with preparing for regulatory inspections (FDA, EMA) as the subject matter expert for contamination control practices.

Forge Biologics provides end-to-end development and manufacturing for gene therapies, using its gene therapy development engine to move ideas from the lab into scalable production. It focuses on AAV-based therapies and operates from Hearth, a large cGMP facility designed for manufacturing at scale. Revenue comes from offering manufacturing services to other companies and researchers, while also developing its own therapies for potential future products. Its goal is to become a leading, integrated manufacturing partner for gene therapies, helping rare genetic-disease programs reach the clinic and market.

Company Size

201-500

Company Stage

Acquired

Total Funding

$870M

Headquarters

Columbus, Ohio

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Eight ASGCT presentations in May 2025 highlight FUEL™ manufacturing innovations.
  • John Maslowski became CEO on October 1, 2024, driving commercial growth.
  • Partnerships with Affinia, Progeria Foundation, and Fractyl expand revenue pipelines.

What critics are saying

  • Ajinomoto diverts resources to larger CDMOs, diluting Forge's AAV focus within 12-24 months.
  • Hearth facility saturates from Progeria, Affinia, Fractyl partnerships, delaying production in 12-18 months.
  • Catalent's $16.5B acquisition floods AAV capacity, undercutting Forge pricing in 6-12 months.

What makes Forge Biologics unique

  • FUEL™ platform boosts AAV productivity, recovery, and quality using Ignition Cells™ and pEMBR™ 2.0.
  • 200,000 sq ft Hearth facility houses 20 cGMP suites with 20,000L bioreactor capacity.
  • End-to-end services span plasmid DNA, AAV manufacturing, and regulatory support.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

401(k) Company Match

Annual Bonus

Paid Parental Leave

Employee Assistance Program

Wellness Program

Onsite Fitness Facility

Company News

University of Pittsburgh
Apr 22nd, 2026
Innovation Institute Reports Record Number of Invention Disclosures, Despite Pandemic

From swimming devices to rare disease gene therapies, Pitt inventors never stop: The Innovation Institute reported a record 394 invention disclosures for last fiscal year, and Director Evan Facher says another robust year is ahead.

Contract Pharma
Mar 3rd, 2026
Progeria Research Foundation, Forge Biologics Enter Gene Therapy Mfg. Pact

Progeria Research Foundation, Forge Biologics enter gene therapy mfg. Pact. Forge Biologics will provide process development and manufacturing services to support gene therapy for ultrarare disease. March 3, 2026 Managing Editor, Contract Pharma The Progeria Research Foundation (PRF), a research organization developing treatments for Hutchinson-Gilford Progeria Syndrome, and Forge Biologics, a manufacturer of gene therapies, entered a manufacturing agreement to support the development and manufacture of SamPro-2, PRF's investigational gene therapy for adolescence with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging. The manufacturing agreement leverages PRF's research-driven Progeria program with Forge's integrated gene therapy capabilities including process development, cGMP manufacturing, FUEL platform technologies, and regulatory consultation. Forge will provide manufacturing services for Investigative New Drug (IND)-enabling studies with SamPro-2, a gene therapy that uses adeno-associated virus (AAV), a commonly utilized delivery vehicle in gene therapy, to deliver a base editing approach designed to correct the single DNA base mutation in the lamin A gene that causes Progeria. "Behind every program like this are patients and families who have waited a long time for progress," said John Maslowski, president and chief executive officer of Forge Biologics. "The Progeria Research Foundation and its Gene Team have shown extraordinary dedication to advancing this science, and we are honored to partner with them. At Forge, we bring that same level of care, expertise, and technical rigor to our manufacturing work as we help advance this program for patients."

PharmaSource
May 15th, 2025
Forge Biologics Partners with Fractyl Health on AAV Manufacturing for Metabolic Gene Therapy

Forge Biologics partners with Fractyl Health on AAV manufacturing for metabolic gene therapy.

BioSpace
May 14th, 2025
Forge Biologics Announces Eight Presentations At The American Society Of Gene And Cell Therapy (Asgct) 28Th Annual Meeting

Oral and poster presentations will highlight data demonstrating the enhanced productivity, recovery, and consistent quality of Forge’s FUEL™ AAV manufacturing platform, addressing the industry's need for more efficient manufacturingCOLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025 in New Orleans, Louisiana. The presentations include two technical session presentations, an oral presentation, and five scientific posters focused on Forge’s FUEL™ platform and manufacturing innovations for gene therapies.“We’re proud to share Forge’s latest manufacturing advancements, underscoring our commitment to innovation as we help clients deliver transformative gene therapies to patients,” said John Maslowski, CEO and President of Forge. “Our experts will highlight how the FUEL™ AAV manufacturing platform, with its advanced technologies and product-specific optimizations, drives significant productivity gains. We’re also excited to present additional talks and posters on key analytical advances as we look toward a future of faster and more comprehensive analytics for product release.”SESSION PRESENTATIONSSponsored Symposium. Title: “Great Science Needs Innovative Manufacturing Technology”. Presenters:David Dismuke, Ph.D., Chief Technology Officer

BioProcess International
Nov 15th, 2024
Affinia and Forge team up to tackle cardiovascular diseases

Affinia Therapeutics announced that it is partnering with Forge Biologics to manufacture clinical trial material under GMP standards.

INACTIVE